Prescient Therapeutics Ltd (ASX:PTX) has opened its share purchase plan (SPP) targeting up to $7 million to help advance its lead cancer therapy PTX-100 through its ongoing Phase 2a clinical program.
Eligible shareholders can subscribe for up to $30,000 of new shares at $0.065 each, representing an 18.8% discount to the 10-day volume-weighted average price and a 9.7% discount to the closing price on 24 August 2026.
The offer opened today and is scheduled to close at 5 pm Sydney time on 8 September 2026.
Funds to advance PTX-100
Most of the proceeds will support development of PTX-100 beyond a Dose Optimisation Committee review targeted for the second half of 2026 and into the next stage of clinical development.
Patient recruitment for the Phase 2a trial is meeting targets, with trial sites operating across Australia, the US and Italy.
Prescient said enrolment in the Phase 2a study had increased from 1 patient to 28 over the past year, while the active clinical site network had expanded to 12 sites.
PTX-100 is being developed for cutaneous T-cell lymphoma (CTCL) and has received US Food and Drug Administration Fast Track designation for relapsed or refractory mycosis fungoides, as well as Orphan Drug Designation for T-cell lymphomas.
Funds may also be allocated to working capital, business development, portfolio management and the evaluation of complementary pipeline opportunities.
Share purchase plan details
Shareholders registered at 7pm Sydney time on 24 August 2026 with an address in Australia or New Zealand are eligible to participate.
Applications range from a minimum of $5,000 to a maximum of $30,000, with new shares expected to be allotted on 15 September and quoted on the ASX from 16 September.
Prescient has also reserved the right to undertake a follow-on placement to sophisticated and professional investors if demand warrants.
Next steps
The key near-term milestone for PTX-100 is the Dose Optimisation Committee review expected later in 2026.
Subject to clinical results, Prescient aims to progress the therapy through further dose optimisation and subsequent development steps towards regulatory approval.
Chief executive James McDonnell will also host a shareholder briefing on 28 August at 11am AEST covering the SPP, use of funds and participation process.
About Prescient Therapeutics
Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and cell therapy enhancement platforms.
Its lead targeted therapy, PTX-100, inhibits geranylgeranyl transferase-1, an enzyme involved in cancer-related Ras signalling pathways. The company is also developing its OmniCAR and CellPryme cell therapy platforms.